zealand_logo_RGB_01.png
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
September 14, 2023 16:00 ET | Zealand Pharma
Company announcement – No. 34 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 14, 2023 – Zealand Pharma A/S...
zealand_logo_RGB_01.png
SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023
September 08, 2023 05:00 ET | Zealand Pharma
Press release – No. 11 / 2023 SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023 Copenhagen, Denmark, September 8, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL)...
zealand_logo_RGB_01.png
Zealand Pharma to participate in upcoming healthcare conferences in September 2023
September 07, 2023 11:00 ET | Zealand Pharma
Press release – No. 10 / 2023 Zealand Pharma to participate in upcoming healthcare conferences in September 2023 Copenhagen, Denmark, September 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL)...
zealand_logo_RGB_01.png
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
August 31, 2023 11:35 ET | Zealand Pharma
Company announcement – No. 33 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
zealand_logo_RGB_01.png
Total number of shares and voting rights in Zealand Pharma at August 31, 2023
August 31, 2023 11:30 ET | Zealand Pharma
Company announcement – No. 32 / 2023  Copenhagen, Denmark, August 31, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on...
zealand_logo_RGB_01.png
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
August 30, 2023 01:33 ET | Zealand Pharma
Company announcement – No. 31 / 2023 Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism US FDA has granted priority review...
zealand_logo_RGB_01.png
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
August 25, 2023 10:45 ET | Zealand Pharma
Company announcement – No. 30 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
zealand_logo_RGB_01.png
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
August 24, 2023 16:00 ET | Zealand Pharma
Company announcement – No. 29 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, August 24, 2023 – Zealand Pharma A/S...
zealand_logo_RGB_01.png
Zealand Pharma Announces Financial Results for the First Half of 2023
August 17, 2023 01:00 ET | Zealand Pharma
Company announcement - No. 28 / 2023 Zealand Pharma Announces Financial Results for the First Half of 2023 Strong progress across R&D pipeline and significant strengthening of the balance...
zealand_logo_RGB_01.png
Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results
August 14, 2023 11:05 ET | Zealand Pharma
Press Release – No. 9 / 2023 Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results Copenhagen, Denmark, August 14, 2023 – a Zealand...